| 14/01/25 | 07:00:05 | 14 Jan 2025 | | Diaceutics Opens US Headquarters | RNS |
| 08/01/25 | 07:00:05 | 8 Jan 2025 | | New Service Launched & First Contract Signed | RNS |
| 03/01/25 | 15:39:25 | 3 Jan 2025 | | PDMR Dealings & Total Voting Rights | RNS |
| 19/12/24 | 08:09:59 | 19 Dec 2024 | | Holding(s) in Company | RNS |
| 17/12/24 | 10:46:07 | 17 Dec 2024 | | Holding(s) in Company | RNS |
| 17/12/24 | 07:00:01 | 17 Dec 2024 | | Diaceutics Wins New $5.1m Contract | RNS |
| 10/12/24 | 15:14:19 | 10 Dec 2024 | | Holding(s) in Company | RNS |
| 05/12/24 | 07:00:16 | 5 Dec 2024 | | Awarded UK Research Institute Grant Funding of £1m | RNS |
| 03/12/24 | 14:24:00 | 3 Dec 2024 | | Total Voting Rights | RNS |
| 28/11/24 | 07:00:06 | 28 Nov 2024 | | Expansion of US Commercial Activities | RNS |
| 05/11/24 | 07:00:02 | 5 Nov 2024 | | Capital Markets Webinar | RNS |
| 04/11/24 | 07:00:08 | 4 Nov 2024 | | Holding(s) in Company | RNS |
| 30/10/24 | 14:58:15 | 30 Oct 2024 | | PDMR Shareholding/Share Incentive Plan | RNS |
| 29/10/24 | 10:27:39 | 29 Oct 2024 | | Board Change Update | RNS |
| 25/10/24 | 07:00:07 | 25 Oct 2024 | | Issue of Share Options/PDMR Shareholdings | RNS |
| 24/10/24 | 12:53:08 | 24 Oct 2024 | | Cancellation of Share Premium Account | RNS |
| 15/10/24 | 07:00:09 | 15 Oct 2024 | | Diaceutics Announces Key Leadership Appointment | RNS |
| 07/10/24 | 13:19:11 | 7 Oct 2024 | | Holding(s) in Company | RNS |
| 07/10/24 | 07:00:07 | 7 Oct 2024 | | Block Listing Return | RNS |
| 02/10/24 | 07:00:07 | 2 Oct 2024 | | PDMR Shareholding/Share Incentive Plan | RNS |
| 01/10/24 | 07:00:10 | 1 Oct 2024 | | Board Changes | RNS |
| 17/09/24 | 07:00:07 | 17 Sept 2024 | | H1 2024 Results - Continued Performance & Growth | RNS |
| 09/09/24 | 07:00:10 | 9 Sept 2024 | | Notice of Results & Presentations | RNS |
| 02/09/24 | 07:00:10 | 2 Sept 2024 | | Appointment of Nominated Adviser and Broker | RNS |
| 30/08/24 | 15:45:00 | 30 Aug 2024 | | PDMR Shareholding/Share Incentive Plan | RNS |
| 27/08/24 | 07:00:07 | 27 Aug 2024 | | Diaceutics Launches Enhanced Rare-Disease Offering | RNS |
| 19/08/24 | 07:00:11 | 19 Aug 2024 | | Enterprise Partnership and Launch of PMx | RNS |
| 05/08/24 | 07:00:03 | 5 Aug 2024 | | Presenting at Canaccord Genuity Growth Conference | RNS |
| 29/07/24 | 18:09:48 | 29 Jul 2024 | | PDMR Shareholding/SIP and TVR | RNS |
| 29/07/24 | 07:00:08 | 29 Jul 2024 | | Issue of Share Options/PDMR Shareholdings | RNS |
| 23/07/24 | 07:05:00 | 23 Jul 2024 | | Board Changes | RNS |
| 23/07/24 | 07:00:06 | 23 Jul 2024 | | Revenue growth of 24% in H1 with 55% now recurring | RNS |
| 11/07/24 | 07:00:10 | 11 Jul 2024 | | Senior Management Appointments | RNS |
| 01/07/24 | 07:00:08 | 1 Jul 2024 | | PDMR Shareholding/SIP and Total Voting Rights | RNS |
| 24/06/24 | 13:15:48 | 24 Jun 2024 | | Result of AGM | RNS |
| 13/06/24 | 07:00:11 | 13 Jun 2024 | | "Precision Medicine in Oncology " Virtual Event | RNS |
| 06/06/24 | 07:00:04 | 6 Jun 2024 | | Diaceutics - Capital Markets Event | RNS |
| 29/05/24 | 08:00:00 | 29 May 2024 | | Notice of AGM and Posting of Annual Report | RNS |
| 28/05/24 | 07:00:17 | 28 May 2024 | | Data to be Presented at 2024 ASCO Annual Meeting | RNS |
| 24/05/24 | 15:01:39 | 24 May 2024 | | PDMR Shareholding/SIP and Total Voting Rights | RNS |
| 23/05/24 | 07:00:15 | 23 May 2024 | | Director / PDMR Shareholding | RNS |
| 21/05/24 | 07:00:09 | 21 May 2024 | | Revenue growth of 22% & order book growth of 57% | RNS |
| 16/05/24 | 07:00:09 | 16 May 2024 | | Two New Enterprise-Wide Engagements | RNS |
| 14/05/24 | 07:00:06 | 14 May 2024 | | Diaceutics - Capital Markets Event | RNS |
| 01/05/24 | 07:00:14 | 1 May 2024 | | Notice of Results & Presentations | RNS |
| 30/04/24 | 07:00:15 | 30 Apr 2024 | | PDMR Shareholding/SIP and TVR | RNS |
| 09/04/24 | 07:00:07 | 9 Apr 2024 | | Appointment of Amie Mc Neice as VP of Marketing | RNS |
| 05/04/24 | 13:40:02 | 5 Apr 2024 | | Block Listing Return | RNS |
| 03/04/24 | 07:00:10 | 3 Apr 2024 | | PDMR Shareholding/Share Incentive Plan | RNS |
| 02/04/24 | 07:00:13 | 2 Apr 2024 | | Director/PDMR/PCA Shareholding & TR1 | RNS |
